HB4650 EngrossedLRB100 17477 SLF 32646 b

1    AN ACT concerning criminal law.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Illinois Controlled Substances Act is
5amended by changing Sections 314.5 and 316 as follows:
 
6    (720 ILCS 570/314.5)
7    Sec. 314.5. Medication shopping; pharmacy shopping.
8    (a) It shall be unlawful for any person knowingly or
9intentionally to fraudulently obtain or fraudulently seek to
10obtain any controlled substance or prescription for a
11controlled substance from a prescriber or dispenser while being
12supplied with any controlled substance or prescription for a
13controlled substance by another prescriber or dispenser,
14without disclosing the fact of the existing controlled
15substance or prescription for a controlled substance to the
16prescriber or dispenser from whom the subsequent controlled
17substance or prescription for a controlled substance is sought.
18    (b) It shall be unlawful for a person knowingly or
19intentionally to fraudulently obtain or fraudulently seek to
20obtain any controlled substance from a pharmacy while being
21supplied with any controlled substance by another pharmacy,
22without disclosing the fact of the existing controlled
23substance to the pharmacy from which the subsequent controlled

 

 

HB4650 Engrossed- 2 -LRB100 17477 SLF 32646 b

1substance is sought.
2    (c) A person may be in violation of Section 3.23 of the
3Illinois Food, Drug and Cosmetic Act or Section 406 of this Act
4when medication shopping or pharmacy shopping, or both.
5    (c-5) Effective January 1, 2018, each prescriber
6possessing an Illinois controlled substances license shall
7register with the Prescription Monitoring Program. Each
8prescriber or his or her designee shall also document an
9attempt to access patient information in the Prescription
10Monitoring Program to assess patient access to controlled
11substances when providing an initial prescription for Schedule
12II narcotics such as opioids, except for prescriptions for
13oncology treatment or palliative care, or a 7-day or less
14supply provided by a hospital emergency department when
15treating an acute, traumatic medical condition. This attempt to
16access shall be documented in the patient's medical record. The
17hospital shall facilitate the designation of a prescriber's
18designee for the purpose of accessing the Prescription
19Monitoring Program for services provided at the hospital.
20    (d) When a person has been identified as having 3 or more
21prescribers or 3 or more pharmacies, or both, that do not
22utilize a common electronic file as specified in Section 20 of
23the Pharmacy Practice Act for controlled substances within the
24course of a continuous 30-day period, the Prescription
25Monitoring Program may issue an unsolicited report to the
26prescribers, dispensers, and their designees informing them of

 

 

HB4650 Engrossed- 3 -LRB100 17477 SLF 32646 b

1the potential medication shopping. If an unsolicited report is
2issued to a prescriber or prescribers, then the report must
3also be sent to the applicable dispensing pharmacy.
4    (e) Nothing in this Section shall be construed to create a
5requirement that any prescriber, dispenser, or pharmacist
6request any patient medication disclosure, report any patient
7activity, or prescribe or refuse to prescribe or dispense any
8medications.
9    (f) This Section shall not be construed to apply to
10inpatients or residents at hospitals or other institutions or
11to institutional pharmacies.
12    (g) Any patient or pharmacist feedback, including grades,
13ratings, or written or verbal statements, in opposition to a
14clinical decision that the prescription of a controlled
15substance is not medically necessary shall not be the basis of
16any adverse action, evaluation, or any other type of negative
17credentialing, contracting, licensure, or employment action
18taken against a prescriber or dispenser.
19(Source: P.A. 99-480, eff. 9-9-15; 100-564, eff. 1-1-18.)
 
20    (720 ILCS 570/316)
21    Sec. 316. Prescription Monitoring Program.
22    (a) The Department must provide for a Prescription
23Monitoring Program for Schedule II, III, IV, and V controlled
24substances that includes the following components and
25requirements:

 

 

HB4650 Engrossed- 4 -LRB100 17477 SLF 32646 b

1        (1) The dispenser must transmit to the central
2    repository, in a form and manner specified by the
3    Department, the following information:
4            (A) The recipient's name and address.
5            (B) The recipient's date of birth and gender.
6            (C) The national drug code number of the controlled
7        substance dispensed.
8            (D) The date the controlled substance is
9        dispensed.
10            (E) The quantity of the controlled substance
11        dispensed and days supply.
12            (F) The dispenser's United States Drug Enforcement
13        Administration registration number.
14            (G) The prescriber's United States Drug
15        Enforcement Administration registration number.
16            (H) The dates the controlled substance
17        prescription is filled.
18            (I) The payment type used to purchase the
19        controlled substance (i.e. Medicaid, cash, third party
20        insurance).
21            (J) The patient location code (i.e. home, nursing
22        home, outpatient, etc.) for the controlled substances
23        other than those filled at a retail pharmacy.
24            (K) Any additional information that may be
25        required by the department by administrative rule,
26        including but not limited to information required for

 

 

HB4650 Engrossed- 5 -LRB100 17477 SLF 32646 b

1        compliance with the criteria for electronic reporting
2        of the American Society for Automation and Pharmacy or
3        its successor.
4        (2) The information required to be transmitted under
5    this Section must be transmitted not later than the end of
6    the next business day after the date on which a controlled
7    substance is dispensed, or at such other time as may be
8    required by the Department by administrative rule.
9        (3) A dispenser must transmit the information required
10    under this Section by:
11            (A) an electronic device compatible with the
12        receiving device of the central repository;
13            (B) a computer diskette;
14            (C) a magnetic tape; or
15            (D) a pharmacy universal claim form or Pharmacy
16        Inventory Control form;
17        (4) The Department may impose a civil fine of up to
18    $100 per day for willful failure to report controlled
19    substance dispensing to the Prescription Monitoring
20    Program. The fine shall be calculated on no more than the
21    number of days from the time the report was required to be
22    made until the time the problem was resolved, and shall be
23    payable to the Prescription Monitoring Program.
24    (b) The Department, by rule, may include in the
25Prescription Monitoring Program certain other select drugs
26that are not included in Schedule II, III, IV, or V. The

 

 

HB4650 Engrossed- 6 -LRB100 17477 SLF 32646 b

1Prescription Monitoring Program does not apply to controlled
2substance prescriptions as exempted under Section 313.
3    (c) The collection of data on select drugs and scheduled
4substances by the Prescription Monitoring Program may be used
5as a tool for addressing oversight requirements of long-term
6care institutions as set forth by Public Act 96-1372. Long-term
7care pharmacies shall transmit patient medication profiles to
8the Prescription Monitoring Program monthly or more frequently
9as established by administrative rule.
10    (d) The Department of Human Services shall appoint a
11full-time Clinical Director of the Prescription Monitoring
12Program.
13    (e) (Blank).
14    (f) Within one year of the effective date of this
15amendatory Act of the 100th General Assembly, the Department
16shall adopt rules requiring all Electronic Health Records
17Systems to interface with the Prescription Monitoring Program
18application program on or before January 1, 2021 to ensure that
19all providers have access to specific patient records during
20the treatment of their patients. These rules shall also address
21the electronic integration of pharmacy records with the
22Prescription Monitoring Program to allow for faster
23transmission of the information required under this Section.
24The Department shall establish actions to be taken if a
25prescriber's Electronic Health Records System does not
26effectively interface with the Prescription Monitoring Program

 

 

HB4650 Engrossed- 7 -LRB100 17477 SLF 32646 b

1within the required timeline.
2    (g) The Department, in consultation with the Advisory
3Committee, shall adopt rules allowing licensed prescribers or
4pharmacists who have registered to access the Prescription
5Monitoring Program to authorize a designee to consult the
6Prescription Monitoring Program on their behalf. The rules
7shall include reasonable parameters concerning a
8practitioner's authority to authorize a designee, and the
9eligibility of a person to be selected as a designee. In this
10subsection (g), "pharmacist" shall include a clinical
11pharmacist employed by and designated by a Medicaid Managed
12Care Organization providing services under Article V of the
13Illinois Public Aid Code under a contract with the Department
14of Health and Family Services for the sole purpose of clinical
15review of services provided to persons covered by the entity
16under the contract to determine compliance with subsections (a)
17and (b) of Section 314.5 of this Act. A managed care entity
18pharmacist shall notify prescribers of review activities.
19(Source: P.A. 99-480, eff. 9-9-15; 100-564, eff. 1-1-18.)
 
20    Section 99. Effective date. This Act takes effect upon
21becoming law.